{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:19:15Z","timestamp":1752229155634,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Gerontol Geriat"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Der Schlaganfall ist eine der Hauptursachen f\u00fcr bleibende Behinderung und Tod; das Risiko steigt mit dem Alter. Der Prim\u00e4r- und Sekund\u00e4rpr\u00e4vention kommt eine hohe Priorit\u00e4t zu. Die Behandlung von Risikofaktoren wie Bluthochdruck, Diabetes mellitus und Hyperlipid\u00e4mie ist neben der Optimierung von Lebensstil und Ern\u00e4hrung ebenso bedeutend wie die Antikoagulation bei Vorhofflimmern. In der Rezidivprophylaxe spielen Thrombozytenfunktionshemmer eine Rolle, Karotisoperation oder Stenting kommen bei ausgew\u00e4hlten Individuen zum Einsatz. F\u00fcr alte Menschen gibt es nur geringe Studienevidenz; eine individualisierte Therapieplanung ber\u00fccksichtigt funktionellen Status und Komorbidit\u00e4ten.<\/jats:p>","DOI":"10.1007\/s00391-024-02336-x","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T14:57:08Z","timestamp":1722956228000},"page":"402-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pr\u00e4vention des isch\u00e4mischen Schlaganfalls im Alter","Prevention of ischemic stroke in old age"],"prefix":"10.1007","volume":"57","author":[{"given":"Bernhard","family":"Iglseder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Sebastian","family":"Mutzenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"12","key":"2336_CR1","doi-asserted-by":"publisher","first-page":"E391","DOI":"10.1016\/j.lpm.2016.10.003","volume":"45","author":"Y B\u00e9jot","year":"2016","unstructured":"B\u00e9jot\u00a0Y et\u00a0al (2016) Epidemiology of stroke in Europe and trends for the 21st\u00a0century. Press Medicale 45(12):E391\u2013E398","journal-title":"Press Medicale"},{"issue":"2","key":"2336_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/gerona\/glr065","volume":"67","author":"RI Lindley","year":"2012","unstructured":"Lindley\u00a0RI (2012) Drug trials for older people. J\u00a0Gerontol A Biol Sci Med Sci 67(2):152\u2013157","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2336_CR3","unstructured":"Olma M. C., R.J., Grau A., Kurth T. et\u00a0al.,. Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und transitorische isch\u00e4mische Attacke: Teil\u00a02, S2k-Leitlinie, 2022, Deutsche Gesellschaft f\u00fcr Neurologie (DGN) und Deutsche Schlaganfall-Gesellschaft (DSG). 2022 29.04.2024; Available from: https:\/\/dgn.org\/leitlinien"},{"issue":"1","key":"2336_CR4","first-page":"15","volume":"23","author":"A Guzik","year":"2017","unstructured":"Guzik\u00a0A, Bushnell\u00a0C (2017) Stroke epidemiology and risk factor management. Continuum 23(1):15\u201339","journal-title":"Continuum"},{"issue":"7653","key":"2336_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","volume":"336","author":"Blood Pressure Lowering Treatment Trialists, C.","year":"2008","unstructured":"Blood Pressure Lowering Treatment Trialists, C. et\u00a0al (2008) Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336(7653):1121\u20131123","journal-title":"BMJ"},{"key":"2336_CR6","doi-asserted-by":"crossref","unstructured":"Warwick J et\u00a0al (2015) No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a\u00a0double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 13:","DOI":"10.1186\/s12916-015-0328-1"},{"issue":"5","key":"2336_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/gerona\/glv228","volume":"71","author":"NM Pajewski","year":"2016","unstructured":"Pajewski\u00a0NM et\u00a0al (2016) Characterizing frailty status in the systolic blood pressure intervention trial. J\u00a0Gerontol A Biol Sci Med Sci 71(5):649\u2013655","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"2336_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jama.2015.7517","volume":"314","author":"A Benetos","year":"2015","unstructured":"Benetos\u00a0A et\u00a0al (2015) Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA 314(2):170\u2013180","journal-title":"JAMA"},{"issue":"5","key":"2336_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1161\/STROKEAHA.113.675140","volume":"44","author":"JM Leyden","year":"2013","unstructured":"Leyden\u00a0JM et\u00a0al (2013) Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke 44(5):1226\u20131231","journal-title":"Stroke"},{"issue":"1","key":"2336_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/heartjnl-2019-314898","volume":"106","author":"S Jame","year":"2020","unstructured":"Jame\u00a0S, Barnes\u00a0G (2020) Stroke and thromboembolism prevention in atrial fibrillation. Heart 106(1):10\u201317","journal-title":"Heart"},{"issue":"7","key":"2336_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archinte.159.7.677","volume":"159","author":"M Man-Son-Hing","year":"1999","unstructured":"Man-Son-Hing\u00a0M et\u00a0al (1999) Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 159(7):677\u2013685","journal-title":"Arch Intern Med"},{"issue":"4","key":"2336_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","volume":"42","author":"D Giacoppo","year":"2021","unstructured":"Giacoppo\u00a0D et\u00a0al (2021) Short dual antiplatelet therapy followed by P2Y inhibitor monotherarpy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a\u00a0systematic review and meta-analysis of randomized clinical trials. Eur Heart\u00a0J 42(4):308\u2013319a","journal-title":"Eur Heart J"},{"key":"2336_CR13","doi-asserted-by":"crossref","unstructured":"Awad K et\u00a0al (2021) Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a\u00a0systematic review and meta-analysis of observational studies. BMC Med 19(1)","DOI":"10.1186\/s12916-021-02009-1"},{"issue":"6","key":"2336_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s12181-022-00575-z","volume":"16","author":"H Rittger","year":"2022","unstructured":"Rittger\u00a0H et\u00a0al (2022) Cholesterol-lowering treatment in elderly patients Consensus paper of the DGK and DGGG. Kardiologie 16(6):456\u2013465","journal-title":"Kardiologie"},{"issue":"10","key":"2336_CR15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2019.03.009","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett\u00a0DK et\u00a0al (2019) 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a\u00a0report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines (vol 74, pg e177, 2019). J\u00a0Am Coll Cardiol 74(10):1429\u20131430","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2336_CR16","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1806802","volume":"380","author":"PD Reaven","year":"2019","unstructured":"Reaven\u00a0PD et\u00a0al (2019) Intensive glucose control in patients with type\u00a02 diabetes-15-year follow-up. N\u00a0Engl J Med 380(23):2215\u20132224","journal-title":"N Engl J Med"},{"issue":"4","key":"2336_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.pcad.2019.08.003","volume":"62","author":"T Acharya","year":"2019","unstructured":"Acharya\u00a0T, Deedwania\u00a0P (2019) Cardiovascular outcome trials of the newer anti-diabetic medications. Prog Cardiovasc Dis 62(4):342\u2013348","journal-title":"Prog Cardiovasc Dis"},{"issue":"19","key":"2336_CR18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP et\u00a0al (2016) Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N\u00a0Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"11","key":"2336_CR19","doi-asserted-by":"publisher","first-page":"E914","DOI":"10.1016\/S2468-2667(22)00222-5","volume":"7","author":"JK Holodinsky","year":"2022","unstructured":"Holodinsky\u00a0JK et\u00a0al (2022) Association between influenza vaccination and risk of stroke in Alberta, Canada: a\u00a0population-based study. Lancet Public Health 7(11):E914\u2013E922","journal-title":"Lancet Public Health"},{"issue":"9287","key":"2336_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PC Group","year":"2001","unstructured":"Group\u00a0PC (2001) Randomised trial of a\u00a0perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358(9287):1033\u20131041","journal-title":"Lancet"},{"issue":"9891","key":"2336_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","volume":"382","author":"OR Benavente","year":"2013","unstructured":"Benavente\u00a0OR et\u00a0al (2013) Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382(9891):507\u2013515","journal-title":"Lancet"},{"issue":"9943","key":"2336_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","volume":"384","author":"J Sundstr\u00f6m","year":"2014","unstructured":"Sundstr\u00f6m\u00a0J et\u00a0al (2014) Blood pressure-lowering treatment based on cardiovascular risk: a\u00a0meta-analysis of individual patient data. Lancet 384(9943):591\u2013598","journal-title":"Lancet"},{"issue":"9602","key":"2336_CR23","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Lewington\u00a0S et\u00a0al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a\u00a0meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 370(9602):1829\u20131839","journal-title":"Lancet"},{"issue":"9493","key":"2336_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent\u00a0C et\u00a0al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267\u20131278","journal-title":"Lancet"},{"key":"2336_CR25","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"GF Hamann","year":"2022","unstructured":"Hamann\u00a0GF, R\u00f6ther\u00a0J, Grau\u00a0A et\u00a0al (2022) Deutsche Schlaganfall-Gesellschaft und Deutsche Gesellschaft f\u00fcr Neurologie. Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und transitorische isch\u00e4mische Attacke: Teil\u00a01, S2k-Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"issue":"3","key":"2336_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2396987319841187","volume":"4","author":"CJM Klijn","year":"2019","unstructured":"Klijn\u00a0CJM et\u00a0al (2019) Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A\u00a0European Stroke Organisation guideline. Eur Stroke\u00a0J 4(3):198\u2013223","journal-title":"Eur Stroke J"},{"issue":"26","key":"2336_CR27","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2303048","volume":"388","author":"U Fischer","year":"2023","unstructured":"Fischer\u00a0U et\u00a0al (2023) Early versus later anticoagulation for stroke with atrial fibrillation. N\u00a0Engl J Med 388(26):2411\u20132421","journal-title":"N Engl J Med"},{"issue":"9678","key":"2336_CR28","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"R Collins","year":"2009","unstructured":"Collins\u00a0R et\u00a0al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849\u20131860","journal-title":"Lancet"},{"issue":"6","key":"2336_CR29","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/01.STR.31.6.1240","volume":"31","author":"ZM Chen","year":"2000","unstructured":"Chen\u00a0ZM et\u00a0al (2000) Indications for early aspirin use in acute ischemic stroke\u2014A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31(6):1240\u20131249","journal-title":"Stroke"},{"issue":"10","key":"2336_CR30","first-page":"1278","volume":"78","author":"Y Pan","year":"2021","unstructured":"Pan\u00a0Y, Elm\u00a0JJ, Li\u00a0H (2021) Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a\u00a0pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials (vol 76, pg 1466, 2019). JAMA Neurol 78(10):1278\u20131278","journal-title":"JAMA Neurol"},{"issue":"10093","key":"2336_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","volume":"390","author":"L Li","year":"2017","unstructured":"Li\u00a0L et\u00a0al (2017) Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a\u00a0population-based cohort study. Lancet 390(10093):490\u2013499","journal-title":"Lancet"},{"issue":"9352","key":"2336_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0140-6736(03)12228-3","volume":"361","author":"PM Rothwell","year":"2003","unstructured":"Rothwell\u00a0PM et\u00a0al (2003) Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361(9352):107\u2013116","journal-title":"Lancet"},{"issue":"10","key":"2336_CR33","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1161\/STROKEAHA.115.009516","volume":"46","author":"JH Voeks","year":"2015","unstructured":"Voeks\u00a0JH et\u00a0al (2015) Mediators of the age effect in the carotid revascularization endarterectomy versus stenting trial (CREST). Stroke 46(10):2868\u20132873","journal-title":"Stroke"}],"container-title":["Zeitschrift f\u00fcr Gerontologie und Geriatrie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-024-02336-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00391-024-02336-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-024-02336-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T13:08:10Z","timestamp":1723208890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00391-024-02336-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1007\/s00391-024-02336-x","relation":{},"ISSN":["0948-6704","1435-1269"],"issn-type":[{"type":"print","value":"0948-6704"},{"type":"electronic","value":"1435-1269"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>B.\u00a0Iglseder:<\/b> A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Honorare f\u00fcr Webinare der Fa. Gr\u00fcnenthal, 02.12.2020: Zentral wirksame Schmerzmedikamente bei geriatrischen Patient*innen: Eine medizinische Entscheidung zwischen Segen und Fluch?, 02.09.2021: Delir und Schmerz (\u2011medikamente).\u00a0\u2013 Aktien der Fa. Roche.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Abteilungsvorstand, Universit\u00e4tsklinik f\u00fcr Geriatrie, Salzburger Landeskliniken Betriebsgesellschaft mbH und Paracelsus Medizinische Universit\u00e4t | Mitgliedschaften: \u00d6sterreichische Gesellschaft f\u00fcr Neurologie, \u00d6sterreichische Gesellschaft f\u00fcr Schlaganfallforschung, \u00d6sterreichische Gesellschaft f\u00fcr Ultraschall in der Medizin, Gesellschaft der Salzburger \u00c4rztinnen und \u00c4rzte, Altersbeirat des Bundesministeriums f\u00fcr Gesundheit und Soziales, Pr\u00e4sident der \u00d6sterreichischen Gesellschaft f\u00fcr Geriatrie und Gerontologie.<b> J.\u00a0S.\u00a0Mutzenbach:<\/b> A.\u00a0Finanzielle Interessen: S.\u00a0Mutzenbach gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: PD Dr. Sebastian Mutzenbach, Facharzt f\u00fcr Neurologie und Intensivmedizin | Stellvertretender Abteilungsvorstand, Leitender und 1. Oberarzt, Stroke Unit und High Care Bereich, Uniklinikum Salzburg, Christian-Doppler-Klinik, Universit\u00e4tsklinik f\u00fcr Neurologie, neurologische Intensivmedizin und Neurorehabilitation der PMU, Ignaz-Harrer-Stra\u00dfe 79, 5020 Salzburg, \u00d6sterreich | Sekret\u00e4r der \u00d6sterreichischen Schlaganfall-Gesellschaft | Mitgliedschaft: \u00d6sterreichische Gesellschaft f\u00fcr Neurologie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}